Morgan Stanley Upgrades Kymera Therapeutics to Overweight, Raises Price Target to $79

Benzinga · 06/03 13:18
Morgan Stanley analyst James Quigley upgrades Kymera Therapeutics (NASDAQ:KYMR) from Equal-Weight to Overweight and raises the price target from $49 to $79.